80 seems overvalued for VKTX

80 is enuf!!! $Viking Therapeutics, Inc.(VKTX)$

While VKTX-2735 has shown promising safety profiles in early studies, ramping up the dosage could potentially introduce unforeseen risks. Investors might fret over increased adverse reactions with higher doses, casting doubt on its commercial viability and market acceptance

tho its potential for significant weight loss, VKTX-2735 faces an uphill battle in a fiercely competitive weight loss drug market. established players like Semaglutide and Tirzepatide already dominate, raising questions about VKTX-2735's ability to carve out a significant market share and achieve commercial success

and VKTX-2735 is still in the clinical trial phase, and its path to market approval depends on regulatory bodies like the FDA. Any delays or setbacks in the regulatory approval process could spell trouble for the stock price

Is VKTX Heading to $100?

Shares of biopharmaceutical stock VKTX soared about 25% . The company announced early positive study results for its oral weight-loss drug. VKTX said the drug's Phase 1 clinical trial focused on evaluating its safety and significantly exceed market expectations. ---------------- Are weight loss drugs good investing choices? Will you add weight loss drugs as they continue to hit new records?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

163

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":288899772190824,"tweetId":"288899772190824","gmtCreate":1711540543368,"gmtModify":1711561595043,"author":{"id":9000000000000542,"authorId":9000000000000542,"authorIdStr":"9000000000000542","name":"JeromeErnest","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[{"themeId":"62983a96987c49e5ab9a76d137efd550","categoryId":"7a15628ce2174325bddc6229505e0d70","name":"Is VKTX Heading to $100?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":62983a96987c49e5ab9a76d137efd550}&rnconfig={\"headerBarHidden\": true}","description":"Shares of biopharmaceutical stock VKTX soared about 25% . The company announced early positive study results for its oral weight-loss drug. \nVKTX said the drug's Phase 1 clinical trial focused on evaluating its safety and significantly exceed market expectations.\n----------------\nAre weight loss drugs good investing choices?\nWill you add weight loss drugs as they continue to hit new records?","image":"https://community-static.tradeup.com/news/54e8a559470eb200009ddc15b793c8a7"}],"images":[],"coverImages":[],"title":"80 seems overvalued for VKTX","html":"<html><head></head><body>80 is enuf!!! <a data-mention-id=\"VKTX\" class=\"teditor-mention\" data-mention-name=\"Viking Therapeutics, Inc.\" href=\"https://ttm.financial/S/VKTX\">$Viking Therapeutics, Inc.(VKTX)$</a> <v-v data-views=\"0\"></v-v>While VKTX-2735 has shown promising safety profiles in early studies, ramping up the dosage could potentially introduce unforeseen risks. Investors might fret over increased adverse reactions with higher doses, casting doubt on its commercial viability and market acceptancetho its potential for significant weight loss, VKTX-2735 faces an uphill battle in a fiercely competitive weight loss drug market. established players like Semaglutide and Tirzepatide already dominate, raising questions about VKTX-2735's ability to carve out a significant market share and achieve commercial successand VKTX-2735 is still in the clinical trial phase, and its path to market approval depends on regulatory bodies like the FDA. Any delays or setbacks in the regulatory approval process could spell trouble for the stock price</body></html>","htmlText":"<html><head></head><body>80 is enuf!!! <a data-mention-id=\"VKTX\" class=\"teditor-mention\" data-mention-name=\"Viking Therapeutics, Inc.\" href=\"https://ttm.financial/S/VKTX\">$Viking Therapeutics, Inc.(VKTX)$</a> <v-v data-views=\"0\"></v-v>While VKTX-2735 has shown promising safety profiles in early studies, ramping up the dosage could potentially introduce unforeseen risks. Investors might fret over increased adverse reactions with higher doses, casting doubt on its commercial viability and market acceptancetho its potential for significant weight loss, VKTX-2735 faces an uphill battle in a fiercely competitive weight loss drug market. established players like Semaglutide and Tirzepatide already dominate, raising questions about VKTX-2735's ability to carve out a significant market share and achieve commercial successand VKTX-2735 is still in the clinical trial phase, and its path to market approval depends on regulatory bodies like the FDA. Any delays or setbacks in the regulatory approval process could spell trouble for the stock price</body></html>","text":"80 is enuf!!! $Viking Therapeutics, Inc.(VKTX)$ While VKTX-2735 has shown promising safety profiles in early studies, ramping up the dosage could potentially introduce unforeseen risks. Investors might fret over increased adverse reactions with higher doses, casting doubt on its commercial viability and market acceptance tho its potential for significant weight loss, VKTX-2735 faces an uphill battle in a fiercely competitive weight loss drug market. established players like Semaglutide and Tirzepatide already dominate, raising questions about VKTX-2735's ability to carve out a significant market share and achieve commercial success and VKTX-2735 is still in the clinical trial phase, and its path to market approval depends on regulatory bodies like the FDA. Any delays or setbacks in the regulatory approval process could spell trouble for the stock price","highlighted":1,"essential":1,"paper":2,"likeSize":163,"commentSize":0,"repostSize":20,"favoriteSize":0,"link":"https://ttm.financial/post/288899772190824","repostId":0,"isVote":1,"tweetType":1,"viewCount":866,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["VKTX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":true,"length":739,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/288899772190824"}